屈臣氏:10條口罩生產線月產量逾1,000萬個
屈臣氏實業飲品製造總經理(市務及業務策劃)蕭健敏於網上記者會指出,現時旗下口罩生產線增至10條,當中9條為生產成人口罩,每月產量逾1,000萬個,如市場有需求絕對會增加生產線,不過現時仍言之尚早。
他續指之前曾委任工廠製造一批小童口罩滿足開學需求,因為現時旗下生產線未有生產幼童口罩,強調無論自家製作抑或與其他工廠合作都絕對會做好「3查9檢」,確保口罩達到最高標準。他指出現時100%口罩都是自家製作,不過倘有特別訂單未能做到亦不排除會與其他廠商合作。
另外公司獲得消委會測試報告後,隨即安排4間獨立實驗室包括該會採用的同一間實驗室為同一批次產品樣本再次進行同樣測試,而所有複檢結果均顯示WatsMask口罩符合ASTM Level 3標準。(el/a) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.